226 related articles for article (PubMed ID: 6893294)
41. m-AMSA in refractory lymphoma. A phase II trial of the Eastern Cooperative Oncology Group.
Keller AM; Tsiatis AA; Neiman RS; Glick JH; Mann RB
Am J Clin Oncol; 1985 Oct; 8(5):449-52. PubMed ID: 3840644
[TBL] [Abstract][Full Text] [Related]
42. Phase II trial of AMSA in patients with advanced or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study.
Bonomi P; Blessing JA; Sedlacek TV; Homesley HD; DiSaia PJ
Cancer Treat Rep; 1983 Feb; 67(2):197-8. PubMed ID: 6687445
[No Abstract] [Full Text] [Related]
43. Phase I and II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide in patients with acute leukemia.
Arlin ZA; Sklaroff RB; Gee TS; Kempin SJ; Howard J; Clarkson BD; Young CW
Cancer Res; 1980 Sep; 40(9):3304-6. PubMed ID: 6933002
[TBL] [Abstract][Full Text] [Related]
44. m-AMSA: a new anticancer agent.
Rozencweig M; Von Hoff DD; Legha SS; Cysyk RL; Muggia FM
Recent Results Cancer Res; 1980; 74():250-7. PubMed ID: 6893753
[TBL] [Abstract][Full Text] [Related]
45. Multiple ventricular extrasystoles following administration of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA).
Falkson G
Cancer Treat Rep; 1980; 64(2-3):358. PubMed ID: 6157470
[No Abstract] [Full Text] [Related]
46. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.
de Jong S; Kooistra AJ; de Vries EG; Mulder NH; Zijlstra JG
Cancer Res; 1993 Mar; 53(5):1064-71. PubMed ID: 8382551
[TBL] [Abstract][Full Text] [Related]
47. Phase II study of high-dose amsacrine (AMSA) and autologous bone marrow transplantation in patients with refractory metastatic breast cancer.
Tannir N; Spitzer G; Schell F; Legha S; Zander A; Blumenschein G
Cancer Treat Rep; 1983 Jun; 67(6):599-600. PubMed ID: 6344995
[No Abstract] [Full Text] [Related]
48. Acute ventricular fibrillation and death during infusion of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA).
Von Hoff DD; Elson D; Polk G; Coltman C
Cancer Treat Rep; 1980; 64(2-3):356-8. PubMed ID: 6931630
[No Abstract] [Full Text] [Related]
49. m-AMSA in epithelial carcinoma of the ovary. A Southwest Oncology Group study.
Hilgers RD; Legha SS; Panettiere FJ; Alberts DS
Am J Clin Oncol; 1983 Jun; 6(3):277-9. PubMed ID: 6687779
[TBL] [Abstract][Full Text] [Related]
50. Amsacrine (m-AMSA) in squamous cell carcinoma of the uterine cervix: a Southwest Oncology Group study.
Hilgers RD; Legha SS; Boutselis JG; Hannigan EV; Stephens RL; Tranum BL; Surwit E
Cancer Treat Rep; 1984 Feb; 68(2):443-4. PubMed ID: 6546533
[No Abstract] [Full Text] [Related]
51. Phase I clinical and pharmacological study of 4'-(9-acridinylamino)-methanesulfon-m-anisidide using an intermittent biweekly schedule.
Van Echo DA; Chiuten DF; Gormley PE; Lichtenfeld JL; Scoltock M; Wiernik PH
Cancer Res; 1979 Oct; 39(10):3881-4. PubMed ID: 476624
[TBL] [Abstract][Full Text] [Related]
52. Toxicity of 4'-(9-acridinylamino)methanesulfon-m-anisidide in exponential- and plateau-phase Chinese hamster cell cultures.
Wilson WR; Giesbrecht JL; Hill RP; Whitmore GF
Cancer Res; 1981 Jul; 41(7):2809-16. PubMed ID: 6894713
[TBL] [Abstract][Full Text] [Related]
53. Phase II trial of AMSA in prostatic cancer.
Natale RB; Yagofa A; Watson RC
Cancer Treat Rep; 1982 Jan; 66(1):208-9. PubMed ID: 6895482
[No Abstract] [Full Text] [Related]
54. A randomized phase II study of m-AMSA (NSC 249992) and neocarzinostatin (NSC 157365) in non-small cell bronchogenic carcinoma. An Eastern Cooperative Group Study.
Ettinger DS; Day R; Ferraro JA; Ruckdeschel JC; Woll JE; Creech RH; Vogl SE
Am J Clin Oncol; 1983 Apr; 6(2):167-70. PubMed ID: 6299093
[TBL] [Abstract][Full Text] [Related]
55. Phase II study of AMSA in patients with advanced ovarian cancer.
Kearsley JH; Coates AS; Fox RM; Tattersall MH; Page J; Levi JA
Cancer Treat Rep; 1982 May; 66(5):1242-3. PubMed ID: 6896295
[No Abstract] [Full Text] [Related]
56. The treatment of melanoma with m-AMSA. A Cancer and Leukemia Group B phase II study.
Amrein PC; Poulin RF; Coleman M; Richards F; Weil M; Kennedy BJ; Carey RW; Green MR; Holland JF; Weinberg V
Am J Clin Oncol; 1984 Jun; 7(3):269-71. PubMed ID: 6547269
[TBL] [Abstract][Full Text] [Related]
57. Divergent activity of derivatives of amsacrine (m-AMSA) towards Lewis lung carcinoma and P388 leukaemia in mice.
Baguley BC; Kernohan AR; Wilson WR
Eur J Cancer Clin Oncol; 1983 Nov; 19(11):1607-13. PubMed ID: 6688994
[TBL] [Abstract][Full Text] [Related]
58. Phase I clinical and pharmacokinetic study of 4'-(9-acridinylamino)-methanesulfon-m-anisidide in children with cancer.
Rivera G; Evans WE; Dahl GV; Yee GC; Pratt CB
Cancer Res; 1980 Nov; 40(11):4250-3. PubMed ID: 6258775
[TBL] [Abstract][Full Text] [Related]
59. Phase II study of AMSA in patients with metastatic breast cancer: a Cancer and Leukemia Group B study.
Amrein PC; Coleman M; Richards F; Poulin RF; Bernhardt B; Ginsberg SJ; Green MR; Morrison A; Cortes E; Kiang D; Weinberg V; Wood WC
Cancer Treat Rep; 1982 May; 66(5):1211-3. PubMed ID: 6896294
[No Abstract] [Full Text] [Related]
60. Phase II study of amsacrine in solid tumors: a report of the EORTC Early Clinical Trial-Group.
De Jager R; Siegenthaler P; Cavalli F; Klepp O; Bramwell V; Joss R; Alberto P; van Glabbeke M; Renard J; Rozencweig M; Hansen HH
Eur J Cancer Clin Oncol; 1983 Feb; 19(2):289-93. PubMed ID: 6687457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
